Medical Innovations

March 21, 2026

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…

BBusiness

February 27, 2026

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks…

BBusiness

January 16, 2026

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…

BBusiness

October 25, 2025

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…

BBusiness

September 26, 2025

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety…

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025